Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Update

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the target of a significant decrease in short interest in December. As of December 31st, there was short interest totalling 12,100 shares, a decrease of 55.4% from the December 15th total of 27,100 shares. Based on an average daily volume of 143,100 shares, the days-to-cover ratio is presently 0.1 days.

OTCMKTS ALPMY opened at $16.51 on Friday. Astellas Pharma has a 12 month low of $14.60 and a 12 month high of $18.46. The stock has a market cap of $30.74 billion, a P/E ratio of 27.43 and a beta of 0.64. The stock’s fifty day moving average price is $16.34 and its 200-day moving average price is $16.77. The company has a current ratio of 1.58, a quick ratio of 1.31 and a debt-to-equity ratio of 0.15.

Astellas Pharma (OTCMKTS:ALPMY) last released its quarterly earnings data on Friday, October 29th. The company reported $0.20 EPS for the quarter. Astellas Pharma had a return on equity of 8.60% and a net margin of 9.29%. The company had revenue of $2.96 billion for the quarter. As a group, analysts forecast that Astellas Pharma will post 0.89 earnings per share for the current fiscal year.

Separately, Zacks Investment Research upgraded Astellas Pharma from a “sell” rating to a “hold” rating in a report on Monday, December 20th.

About Astellas Pharma

Astellas Pharma, Inc engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases.

Read More: Options Trading – Understanding Strike Price

Receive News & Ratings for Astellas Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astellas Pharma and related companies with's FREE daily email newsletter.